Dynamic SUMOylation is linked to the activity cycles of androgen receptor in the cell nucleus

Molecular and Cellular Biology

Volumn 32, Issue 20, 2012, Pages 4195-4205

  Kaikkonen, Sanna ^a   Sutinen, Päivi ^a   Paakinaho, Ville ^a   Rahkama, Vesa ^a   Palvimo, Jorma J ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; SUMO 2 PROTEIN; SUMO 3 PROTEIN;

ARTICLE; CANCER CELL CULTURE; CELL NUCLEUS; CELL NUCLEUS MATRIX; CELL STRESS; CHROMATIN; CONTROLLED STUDY; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HYPERTHERMIA; MALE; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN STABILITY; STEADY STATE; SUMOYLATION;

ANDROGENS; CELL LINE, TUMOR; CELL NUCLEUS; CHROMATIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS; SUMOYLATION; UBIQUITINS;

EID: 84868676813     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00753-12     Document Type: Article

References (55)

1. Bertolotto C, et al. 2011. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 480: 94-98.
2. Boccardo F, et al. 2003. Nuclear matrix proteins changes in cancerous prostate tissues and their prognostic value in clinically localized prostate cancer. Prostate 55:259-264.
3. Campbell LA, et al. 2008. Decreased recognition of SUMO-sensitive target genes following modification of SF-1 (NR5A1). Mol. Cell. Biol. 28:7476-7486.
4. Chalkiadaki A, Talianidis I. 2005. SUMO-dependent compartmentalization in promyelocytic leukemia protein nuclear bodies prevents the access of LRH-1 to chromatin. Mol. Cell. Biol. 25:5095-5105.
5. Gareau JR, Lima CD. 2010. The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat. Rev. Mol. Cell Biol. 11:861-871.
6. Geiss-Friedlander R, Melchior F. 2007. Concepts in sumoylation: a decade on. Nat. Rev. Mol. Cell Biol. 8:947-956.
7. Golebiowski F, et al. 2009. System-wide changes to SUMO modifications in response to heat shock. Sci. Signal. 2:ra24. doi:10.1126/ scisignal.2000282.
8. Guo B, Sharrocks AD. 2009. Extracellular signal-regulated kinase mitogen-activated protein kinase signaling initiates a dynamic interplay between sumoylation and ubiquitination to regulate the activity of the transcriptional activator PEA3. Mol. Cell. Biol. 29:3204-3218.
9. He DC, Nickerson JA, Penman S. 1990. Core filaments of the nuclear matrix. J. Cell Biol. 110:569-580.
10. Heemers HV, Tindall DJ. 2007. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr. Rev. 28:778-808.
11. Heun P. 2007. SUMOrganization of the nucleus. Curr. Opin. Cell Biol. 19:350-355.
12. John S, et al. 2009. Kinetic complexity of the global response to glucocorticoid receptor action. Endocrinology 150:1766-1774.
13. Kaikkonen S, et al. 2009. SUMO-specific protease 1 (SENP1) reverses the hormone-augmented SUMOylation of androgen receptor and modulates gene responses in prostate cancer cells. Mol. Endocrinol. 23:292-307.
14. Karvonen U, Kallio PJ, Jänne OA, Palvimo JJ. 1997. Interaction of androgen receptors with androgen response element in intact cells. Roles of amino- and carboxyl-terminal regions and the ligand. J. Biol. Chem. 272:15973-15979.
15. Kim JH, Baek SH. 2009. Emerging roles of desumoylating enzymes. Biochim. Biophys. Acta 1792:155-162.
16. Klokk TI, et al. 2007. Ligand-specific dynamics of the androgen receptor at its response element in living cells. Mol. Cell. Biol. 27:1823-1843.
17. Knudsen KE, Penning TM. 2010. Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol. Metab. 21:315-324.
18. Kotaja N, Karvonen U, Jänne OA, Palvimo JJ. 2002. PIAS proteins modulate transcription factors by functioning as SUMO-1 ligases. Mol. Cell. Biol. 22:5222-5234.
19. Krumova P, et al. 2011. Sumoylation inhibits alpha-synuclein aggregation and toxicity. J. Cell Biol. 194:49-60.
20. Lallemand-Breitenbach V, et al. 2008. Arsenic degrades PML or PMLRARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat. Cell Biol. 10:547-555.
21. Lee FY, et al. 2011. Eliminating SF-1 (NR5A1) sumoylation in vivo results in ectopic hedgehog signaling and disruption of endocrine development. Dev. Cell 21:315-327.
22. Lee HY, et al. 2009. Controlling hematopoiesis through sumoylationdependent regulation of a GATA factor. Mol. Cell 36:984-995.
23. Lin DY, et al. 2006. Role of SUMO-interacting motif in Daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors. Mol. Cell 24:341-354.
24. Makkonen H, Kauhanen M, Jaaskelainen T, Palvimo JJ. 2011. Androgen receptor amplification is reflected in the transcriptional responses of Vertebral-Cancer of the Prostate cells. Mol. Cell Endocrinol. 331:57-65.
25. Makkonen H, Kauhanen M, Paakinaho V, Jaaskelainen T, Palvimo JJ. 2009. Long-range activation of FKBP51 transcription by the androgen receptor via distal intronic enhancers. Nucleic Acids Res. 37:4135-4148.
26. Marcelli M, et al. 2006. Quantifying effects of ligands on androgen receptor nuclear translocation, intranuclear dynamics, and solubility. J. Cell. Biochem. 98:770-788.
27. Mukherjee S, Thomas M, Dadgar N, Lieberman AP, Iniguez-Lluhi JA. 2009. Small ubiquitin-like modifier (SUMO) modification of the androgen receptor attenuates polyglutamine-mediated aggregation. J. Biol. Chem. 284:21296-21306.
28. Müller S, Matunis MJ, Dejean A. 1998. Conjugation with the ubiquitinrelated modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J. 17:61-70.
29. Ogawa H, Komatsu T, Hiraoka Y, Morohashi K. 2009. Transcriptional suppression by transient recruitment of ARIP4 to sumoylated nuclear receptor Ad4BP/SF-1. Mol. Biol. Cell 20:4235-4245.
30. Ouyang J, Gill G. 2009. SUMO engages multiple corepressors to regulate chromatin structure and transcription. Epigenetics 4:440-444.
31. Partin AW, et al. 1993. Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer. Cancer Res. 53:744-746.
32. Poukka H, Karvonen U, Jänne OA, Palvimo JJ. 2000. Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). Proc. Natl. Acad. Sci. U. S. A. 97:14145-14150.
33. Rosendorff A, et al. 2006. NXP-2 association with SUMO-2 depends on lysines required for transcriptional repression. Proc. Natl. Acad. Sci. U. S. A. 103:5308-5313.
34. Rosonina E, Duncan SM, Manley JL. 2010. SUMO functions in constitutive transcription and during activation of inducible genes in yeast. Genes Dev. 24:1242-1252.
35. Rytinki MM, Kaikkonen S, Pehkonen P, Jaaskelainen T, Palvimo JJ. 2009. PIAS proteins: pleiotropic interactors associated with SUMO. Cell. Mol. Life Sci. 66:3029-3041.
36. Rytinki MM, Kaikkonen S, Sutinen P, Palvimo JJ. 2011. Analysis of androgen receptor SUMOylation. Methods Mol. Biol. 776:183-197.
37. Rytinki MM, Palvimo JJ. 2008. SUMOylation modulates the transcription repressor function of RIP140. J. Biol. Chem. 283:11586-11595.
38. Rytinki MM, Palvimo JJ. 2009. SUMOylation attenuates the function of PGC-1alpha. J. Biol. Chem. 284:26184-26193.
39. Saitoh H, Hinchey J. 2000. Functional heterogeneity of small ubiquitinrelated protein modifiers SUMO-1 versus SUMO-2/3. J. Biol. Chem. 275: 6252-6258.
40. Sarge KD, Park-Sarge OK. 2009. Sumoylation and human disease pathogenesis. Trends Biochem. Sci. 34:200-205.
41. Schimmel J, et al. 2008. The ubiquitin-proteasome system is a key component of the SUMO-2/3 cycle. Mol. Cell. Proteomics 7:2107-2122.
42. Shen MM, Abate-Shen C. 2010. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 24:1967-2000.
43. Stielow B, et al. 2008. Identification of SUMO-dependent chromatinassociated transcriptional repression components by a genome-wide RNAi screen. Mol. Cell 29:742-754.
44. Sun H, Leverson JD, Hunter T. 2007. Conserved function of RNF4 family proteins in eukaryotes: targeting a ubiquitin ligase to SUMOylated proteins. EMBO J. 26:4102-4112.
45. Tang Y, DeFranco DB. 1996. ATP-dependent release of glucocorticoid receptors from the nuclear matrix. Mol. Cell. Biol. 16:1989-2001.
46. Tatham MH, et al. 2008. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat. Cell Biol. 10:538-546.
47. Tatham MH, et al. 2001. Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9. J. Biol. Chem. 276:35368-35374.
48. Tatham MH, Matic I, Mann M, Hay RT. 2011. Comparative proteomic analysis identifies a role for SUMO in protein quality control. Sci. Signal. 4:rs4. doi:10.1126/scisignal.2001484.
49. Treuter E, Venteclef N. 2011. Transcriptional control of metabolic and inflammatory pathways by nuclear receptor SUMOylation. Biochim. Biophys. Acta 1812:909-918.
50. van Hagen M, Overmeer RM, Abolvardi SS, Vertegaal AC. 2010. RNF4 and VHL regulate the proteasomal degradation of SUMO-conjugated Hypoxia-Inducible Factor-2alpha. Nucleic Acids Res. 38:1922-1931.
51. Venteclef N, et al. 2010. GPS2-dependent corepressor/SUMO pathways govern anti-inflammatory actions of LRH-1 and LXRbeta in the hepatic acute phase response. Genes Dev. 24:381-395.
52. Wilkinson KA, Henley JM. 2010. Mechanisms, regulation and consequences of protein SUMOylation. Biochem. J. 428:133-145.
53. Yang SH, Sharrocks AD. 2004. SUMO promotes HDAC-mediated transcriptional repression. Mol. Cell 13:611-617.
54. Yang W, Sheng H, Warner DS, Paschen W. 2008. Transient global cerebral ischemia induces a massive increase in protein sumoylation. J. Cereb. Blood Flow Metab. 28:269-279.
55. Yokoyama S, et al. 2011. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 480:99-103.